Prashanth Prithviraj

Melbourne Austin Branch
Heidelberg, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma.

Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma.

Journal: Cancers

Published: April 28, 2026

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Journal: Clinical genitourinary cancer

Published: January 16, 2026

Advances in CRISPR/Cas systems-based cell and gene therapy.

Advances in CRISPR/Cas systems-based cell and gene therapy.

Journal: Progress in molecular biology and translational science

Published: September 12, 2024

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.

Journal: BJU international

Published: November 21, 2023

The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits.

The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits.

Journal: Journal of biomedical science

Published: July 20, 2023

In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.

In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.

Journal: Cancers

Published: March 23, 2023

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.

Journal: Current oncology (Toronto, Ont.)

Published: August 19, 2022

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer.

Journal: International journal of molecular sciences

Published: December 03, 2021

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma.

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma.

Journal: Frontiers in medicine

Published: August 30, 2021

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study.

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study.

Journal: Journal of clinical medicine

Published: March 24, 2021

Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.

Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.

Journal: Journal of clinical medicine

Published: March 21, 2021

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 06, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026